These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 8364001)

  • 1. Pharmacological control of hypertriglyceridemia.
    Franceschini G; Paoletti R
    Cardiovasc Drugs Ther; 1993 Jun; 7(3):297-302. PubMed ID: 8364001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs affecting triglycerides.
    Capurso A
    Cardiology; 1991; 78(3):218-25. PubMed ID: 1868499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
    Morton AM; Furtado JD; Lee J; Amerine W; Davidson MH; Sacks FM
    J Clin Lipidol; 2016; 10(6):1442-1451.e4. PubMed ID: 27919362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triglyceride as a risk factor for coronary artery disease.
    Gotto AM
    Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians.
    Bays H
    Drugs Today (Barc); 2008 Mar; 44(3):205-46. PubMed ID: 18536782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for severe hypertriglyceridemia treatment, are there new strategies?
    Filippatos TD; Elisaf MS
    Curr Vasc Pharmacol; 2014; 12(4):598-616. PubMed ID: 23627980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hypertriglyceridemia in the diabetic patient.
    Jialal I; Amess W; Kaur M
    Curr Diab Rep; 2010 Aug; 10(4):316-20. PubMed ID: 20532703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
    Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ
    Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertriglyceridemia and cardiovascular risk reduction.
    Jacobson TA; Miller M; Schaefer EJ
    Clin Ther; 2007 May; 29(5):763-777. PubMed ID: 17697898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol.
    Szapary PO; Rader DJ
    Curr Opin Pharmacol; 2001 Apr; 1(2):113-20. PubMed ID: 11714084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of triglycerides in cardiovascular risk.
    Gandotra P; Miller M
    Curr Cardiol Rep; 2008 Nov; 10(6):505-11. PubMed ID: 18950562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV
    Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia.
    Maki KC; Guyton JR; Orringer CE; Hamilton-Craig I; Alexander DD; Davidson MH
    J Clin Lipidol; 2016; 10(4):905-914. PubMed ID: 27578122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol.
    Savinova OV; Fillaus K; Harris WS; Shearer GC
    Atherosclerosis; 2015 Jun; 240(2):520-5. PubMed ID: 25932792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The triglyceride connection in atherosclerosis.
    Geurian K; Pinson JB; Weart CW
    Ann Pharmacother; 1992 Sep; 26(9):1109-17. PubMed ID: 1421678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Residual risk: The roles of triglycerides and high density lipoproteins].
    Grammer T; Kleber M; Silbernagel G; Scharnagl H; März W
    Dtsch Med Wochenschr; 2016 Jun; 141(12):870-7. PubMed ID: 27305303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.